| Company Name | Amount Raised | Type of Fundraise | Country | Date |
| Private Company Financings |
| BridgeBio | $1 billion | Series A | US | 1 July |
| Celea Therapeutics | $180 million | | US | 2 July |
| FORE Biotherapeutics | $67.4 million | Series D | France | 13 July |
| Draig Therapeutics | $65 million | Series B | UK | 14 July |
| Chai Discovery | $400 million | Series C | US | 14 July |
| AdvanCell | $315 million | Series D | US/ Australia | 15 July |
| Crystalys Therapeutics | $130 million | Series B | US | 22 July |
| Claris Bio | $118 million | Series B | US | 28 July |
| Ratio Therapeutics | $70 million | Series C | US | 31 July |
| Expedition Therapeutics | $115 million | Series B | US | 5 August |
| Mironid | $46 million | Series B | UK | 5 August |
| Vedanta Biosciences | $60 million | | US | 6 August |
| LifeMine Therapeutics | $263 million | Series E/D | US | 6 August |
| Epicrispr Biotechnologies | $90 million | Series C | US | 11 August |
| Vaderis Therapeutics | $152 million | Series B | Switzerland | 11 August |
| Infinimmune | $75 million | Series A | US | 11 August |
| Epicrispr Biotechnologies | $90 million | Series C | US | 11 August |
| Vaderis Therapeutics | $152 million | Series B | Switzerland | 11 August |
| InduPro | $77 million | Series B | US | 12 August |
| Abcuro | $66 million | Series D | US | 18 August |
| Public Company Financings |
| MeiraGTx | $400 million | | US | 7 July |
| Alto Neuroscience | $100 million | Registered direct offering | US | 13 July |
| Erasca | $550 million | Public offering | US | 13 July |
| Avere Therapeutics | $320 million | Private placement | US | 14 July |
| Mentari Therapeutics | $200 million | Private placement | US | 22 July |
| Scribe Therapeutics | $128.7 million | Public offering | US | 23 July |
| Processa Pharmaceuticals | $200 million | Private placement | US | 29 July |
| Caldera Therapeutics | $278 million | Private placement | US | 29 July |
| Apnimed | $192 million | Public offering | US | 30 July |
| Attovia Therapeutics | $289 million | Public offering | US | 4 August |
| Braveheart Bio | $382.5 million | Public offering | US | 5 August |
| BlossomHill Therapeutics | $150 million | Public offering | US | 6 August |
| Latigo Biotherapeutics | $345.6 million | Public offering | US | 6 August |
| Silence Therapeutics | $175 million | Public offering | UK | 11 August |
| AbCellera | $200 million | Public offering | Canada | 13 August |
| Slate Medicines | $245 million | Private placement | US | 17 August |
| Amylyx Pharmaceuticals | $500.2 million | Public offering | US | 19 August |
| Ambros Therapeutics | $150 million | Private placement | US | 21 August |
| Immatics | $150 million | Public offering | Germany | 25 August |